One hundred and forty three multitransfused patients with hereditary haemostatic disorders were examined for evidence of disease related to the acquired immune deficiency syndrome (AIDS). Ninety nine patients with severe haemophilia A were tested for anti-HTLV-III and 76 were found to be positive. All except one of these seropositive patients had received commercial factor VIII concentrates at some time. Eighteen patients with haemophilia B were tested and all were anti-HTLV-III negative. Three out of 36 sexual partners of patients with haemophilia A positive for anti-HTLV-III were also seropositive. One, who had recently received blood transfusions, had AIDS with Pneumocystis carinii pneumonia. Three patients with severe haemophilia A died from AIDS. A further 30 haemophiliacs had AIDS
Introduction
Most people with severe haemophilia depend on frequent intravenous injections of clotting factor prepared from human plasma. Both factor VIII for haemophilia A and factor IX for haemophilia B (Christmas disease) are available as lyophilised concentrates, which are convenient for the rapid delivery of treatment needed to arrest or prevent bleeds. These concentrates are made by fractionating plasma obtained Several thousand donations are required per batch of concentrate. Thus each patient using a concentrate is exposed to material from many donors every time he injects himself, and viral contamination of the source plasma through individual contaminated donations has become a well recognised hazard in the management of haemophilias. All patients using multidonor material can be expected to have been repeatedly challenged by hepatitis B, hepatitis non-A non-B, and the human parvovirus. They have also been repeatedly challenged by proteins and other plasma constituents variously altered in the manufacturing process.
In 1982 the first report of a link between the acquired immunodeficiency syndrome (AIDS) and transfusion of a blood product appeared,' and since 1983 it has become increasingly likely that immunological disturbances in haemophilia are caused by the aetiological agent for AIDS rather than by any alloantigenic response to denatured protein. The description of the AIDS virus, variously called lymphadenopathy associated virus (LAV)2 and the human T cell lymphotropic virus type III (HTLV-III),3 and the development of tests for its antibody (anti-HTLV-III) have permitted identification of previous exposure to HTLV-III. The presence of viral contamination in biological materials from multidonor source plasma has been confirmed by the demonstration of virus infection in recipients, and the prevalence of anti-HTLV-III in severely affected haemophiliacs can be as high as 90%. 4 (table I) .
Since the start of the programme follow up in Newcastle has included repeated clinical examination and musculoskeletal assessment, monitoring of blood counts (including haemoglobin and white cell and platelet counts), liver function tests, urine analysis, and, when indicated, radiology and specialist referral. Children are examined at least once every six months and adults at least yearly. slides were washed in phosphate buffered saline, mounted with coverslips in glycerol saline, and examined by fluorescent microscopy under epi-illumination. Positive samples showed the characteristic surface and cytoplasmic location of antigen within the cells. HT H9 cells were made available through the generosity of Dr R C Gallo, National Cancer Institute, Maryland, USA.
In Immunological studies were performed on all four patients with AIDS and five patients with the AIDS related complex who were seropositive for anti-HTLV-III (table VI). All patients showed major abnormalities, the most consistent and striking being a reduction in the absolute T4 count even in patients with normal total lymphocyte counts. Apart from the abnormalities of T cell function, these patients also showed other consistent immunological abnormalities that are features of HTLV-III infection, including hypergammaglobulinaemia and raised serum 2 microglobulin concentrations.
Discussion
Our results show a high incidence of HTLV-III related disease in a multitransfused population of haemophiliacs exposed since the early 1970s to concentrates prepared from thousands of plasma donations. Nearly all patients with severe haemophilia A had at some time received factor VIII commercial concentrates and most of them were seropositive to HTLV-III. The few patients with haemophilia B within our population were all seronegative and had been exposed only to NHS factor IX concentrate from volunteer donors. However, seroconversion5 and, in one case, full blown AIDS have occurred in similar groups of patients with haemophilia B in the UK, indicating that the UK donor panel has included HTLV-III infected donors. All our patients now receive heat treated factor VIII or IX concentrates, except for some mildly affected patients, people with von Willebrand's disease, and young children. These patients are treated with either desmopressin, when this is likely to raise factor VIIIC levels or shorten bleeding times, or, when available, with cryoprecipitate or fresh frozen plasma from a special donor panel of seronegative people. We are reluctant to use heat treated concentrates rather than cryoprecipitate or fresh frozen plasma, as advocated by Bloom and his colleagues,6 because of the high incidence of non-A non-B hepatitis which affects patients treated with multidonor products.
Our experience with florid AIDS is in keeping with that of Evatt and colleagues,7 which suggests that older patients are at increased risk of developing severe disease after HTLV-III infection; three of the four people with AIDS were aged over 60 when Pneumocystis carinii pneumonia was first diagnosed. Because of this we are now prescribing prophylactic therapy with pyrimethamine and sulfadoxine (Fansidar) for older patients with AIDS related complex.8
Other workers have shown that seroconversion for anti-HTLV-III in haemophiliacs occurred as early as 1979-81.5 10 Although we have no direct evidence of the timing of seroconversion in our patient population, it probably did occur around this time, if not earlier. The widespread use of multidonor concentrates in Newcastle dates from 1973-4, and this may be the reason for both the high prevalence of seropositivity and the high incidence of virus related disease in our population when compared with other patient groups in the United Kingdom. In our study patients with severe disease did not use significantly more factor VIII than those without AIDS or AIDS related disease, nor did they use significantly more blood products than similar patients treated elsewhere. It may be that cofactors in addition to HTLV-III infection are needed to produce severe disease. Further comparative studies will be needed to determine what, in addition to age, these might be. Given that seroconversion probably occurred as long ago as the late 1970s in many patients it is some comfort to presume that most of our patients have already lived through the median incubation period for AIDS1' and remain in good general health. Further follow up will be needed to confirm this impression, which may simply reflect the slow development of AIDS related disease in some patients. 12 A disturbing feature of this survey is the preliminary evidence for heterosexual transmission of HTLV-III in three regular sexual partners of patients with severe haemophilia A. Apart from an eight unit blood transfusion from volunteer donors in one woman, no other possible risk factors are known for these women. Our results are in keeping with those of others,"-" and are of profound importance for haemophilic families. To counsel that vaginal intercourse should always be protected by condom and that couples should be advised not to start a family until we know more about the degree of risk of fetal transmission"8 is bad enough. There is a most urgent need to put this advice in the context of real versus perceived risk.
Our immunological results confirm those of others' 7 in showing that the absolute reduction of T4 cells in AIDS is a more accurate predictor of overall immune function than the ratio of T4:T8 or skin testing for cell mediated immunity. Indeed, it is striking that one patient in this series with AIDS and another two with AIDS related complex still had intact antigen recall despite profound T4 lymphopenia, a situation which has been observed previously. ' the consulting room or the family home that many of those worried by AIDS can be helped. Consideration must also be given to the well being of staff, many of whom have known affected families for years and have watched the hitherto successful application of home therapy and prophylaxis. To cope we think it imperative that the medical, nursing, social work, and laboratory support provided to every centre treating people in any group at risk, including haemophilia centres, should be assessed as a matter of urgency. Extra support is also needed by the voluntary societies concerned with the care of patients with AIDS in the community.
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Appendix: Centres for Disease Control Surveillance definitions AIDS is (a) the presence of reliably diagnosed disease at least moderately predictive of cellular immune deficiency, and (b) the absence of an underlying cause for the immune deficiency or of any defined cause for reduced resistance to the disease. AIDS related complex is a condition in which a person must have two or more symptoms or signs of specific chronic unexplained conditions for three months or longer, together with two or more abnormal laboratory values. The symptoms and signs include non-inguinal lymphadenopathy, weight loss, fever, diarrhoea, fatigue-malaise, and night sweats and the laboratory studies include measurements of lymphocyte subsets and other blood cells, increased serum globulin concentrations, and measurements showing reduction in immune response. To fulfil the criteria of generalised lymphadenopathy at least two extrainguinal sites must be affected for at least three months in the absence of any current illness or drug known to cause lymphadenopathy.
These cross sectional data showed a significant linear association (p <0 001) between consumption of coffee in men and plasma cholesterol and low density lipoprotein cholesterol concentrations. Men who drank five cups of coffee or more had plasma cholesterol concentrations about 0 5 mmol/l (20 mg/100 ml) higher than non-drinkers after controlling for age, ethnicity, body mass, education, season of year, smoking, tea drinking, and dietary intake of fat and carbohydrates. In women adjusted mean plasma cholesterol concentration was 0-34 mmol/l (13 mg/100 ml) higher in coffee drinkers grouped together (p <0 01). The test for a linear trend was not significant. The association in both sexes was largely with the low density lipoprotein cholesterol fraction. High density lipoprotein cholesterol concentrations were somewhat increased in women who drank coffee (p <0 01 for a linear trend) but not in men. Tea drinking was not associated with unadjusted plasma cholesterol concentrations in either sex. Male tea drinkers, but not female, had slightly higher adjusted plasma cholesterol concentrations than non-drinkers (015 mmol/l (6 mg/100 ml), p=004). No dose response relation was evident.
